These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32683146)

  • 1. Umbrella branding in pharmaceutical markets.
    Suppliet M
    J Health Econ; 2020 Sep; 73():102324. PubMed ID: 32683146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Information shocks and pharmaceutical firms' marketing efforts: Evidence from the Chantix black box warning removal.
    Lawler EC; Skira MM
    J Health Econ; 2022 Jan; 81():102557. PubMed ID: 34896791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.
    Feldman R; Lobo F
    Eur J Health Econ; 2013 Aug; 14(4):667-75. PubMed ID: 22815099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does brand differentiate pharmaceuticals?
    Bednarik J
    Neuro Endocrinol Lett; 2005 Dec; 26(6):635-52. PubMed ID: 16380705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do coverage mandates affect direct-to-consumer advertising for pharmaceuticals? Evidence from parity laws.
    Nathenson R; Richards MR
    Int J Health Econ Manag; 2018 Sep; 18(3):321-336. PubMed ID: 29380108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parallel trade of pharmaceuticals: The Danish market for statins.
    Méndez SJ
    Health Econ; 2018 Feb; 27(2):333-356. PubMed ID: 28868645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical advertising and Medicare Part D.
    Lakdawalla D; Sood N; Gu Q
    J Health Econ; 2013 Dec; 32(6):1356-67. PubMed ID: 24308884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The legal and ethical dimensions of direct-to-consumer advertising of prescription drugs: the case of Pfizer and Lipitor in the United States.
    Koku PS
    Health Mark Q; 2021; 38(1):23-34. PubMed ID: 34219606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct to consumer advertising in pharmaceutical markets.
    Brekke KR; Kuhn M
    J Health Econ; 2006 Jan; 25(1):102-30. PubMed ID: 16280182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of generic entry in the regulated Taiwanese prescription drug market.
    Liu YM; Cheng JS
    Health Policy; 2012 Dec; 108(2-3):228-35. PubMed ID: 23020970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-to-consumer prescription drug advertising: history, regulation, and issues.
    Huh J; DeLorme DE; Reid LN; An S
    Minn Med; 2010 Mar; 93(3):50-2. PubMed ID: 20429178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communication Strategies in Direct-to-Consumer Prescription Drug Advertising (DTCA): Application of the Six Segment Message Strategy Wheel.
    Ju I; Park JS
    J Health Commun; 2015; 20(5):546-54. PubMed ID: 25794304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals.
    Vogel RJ; Ramachandran S; Zachry WM
    Clin Ther; 2003 Jan; 25(1):309-29. PubMed ID: 12637129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with drug shortages in Canada: a retrospective cohort study.
    Zhang W; Guh DP; Sun H; Lynd LD; Hollis A; Grootendorst P; Anis AH
    CMAJ Open; 2020; 8(3):E535-E544. PubMed ID: 32873582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awareness of and attitudes toward direct-to-consumer prescription drug advertising among young adults.
    Alperstein NM
    Health Mark Q; 2014; 31(3):231-45. PubMed ID: 25120044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical direct-to-consumer advertising and US Hispanic patient-consumers.
    Barker KK; Vasquez Guzman CE
    Sociol Health Illn; 2015 Nov; 37(8):1337-51. PubMed ID: 26235537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are pharmaceutical marketing decisions calibrated to communications effects?
    Cavusgil E; Calantone R
    Health Mark Q; 2011 Oct; 28(4):317-36. PubMed ID: 22054028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.
    Mintzes B; Morgan S; Wright JM
    PLoS One; 2009 May; 4(5):e5699. PubMed ID: 19479084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.